In Regeneron Pharmaceuticals, Inc v Canada (AG), 2023 FC 768, the Federal Court granted Regeneron’s
application to add an inventor to its issued patent, which was the subject of pending litigation. The Court was satisfied, based on the evidence, that the omission of the inventor was made by inadvertence or mistake and not for the purpose of delay.
While Regeneron did not provide affidavits from the already named inventors, the Court noted that this was not a requirement, and that the balance of the evidence favoured granting the application. For example, the Court considered that the same amendment
to inventorship was accepted by the Canadian and US Patent Offices in respect of related patent applications.
Finally, the Court found that granting the application would not impact any third-party rights, as the parties to the ongoing litigation were notified of the application and did not seek to intervene.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Declaration of infringement does not preclude further NOA based on invalidity
On June 28, 2023, Manson J. of the Federal Court dismissed Janssen’s motion for summary judgment in actions relating to Janssen’s patent for dosing regimens of paliperidone palmitate (INVEGA SUSTENNA)...Read More -
Minister of Health reasonable in deciding patent for Janssen’s STELARA was ineligible for listing against SNDSs
On July 17, 2023, Justice Aylen of the Federal Court dismissed Janssen’s application for judicial review of the decision of the Office of Submissions and Intellectual Property refusing to list Canadia...Read More -
Federal Court of Appeal upholds Health Canada’s decision to designate Lifestyle Patch a Natural Health Product
In Le-Vel Brands, LLC v The Attorney General Of Canada, 2023 FCA 177, the Federal Court of Appeal held that the Federal Court properly determined that Health Canda reasonably decided that Le-Vel Bran...Read More